Cargando…
Serum NGAL to Clinically Distinguish Cholangiocarcinoma from Benign Biliary Tract Diseases
Aim. To determine whether the serum level of NGAL can discriminate cholangiocarcinoma from benign biliary tract disease in patients. Methods. This study was performed according to a prospective-specimen-collection, retrospective-blinded-evaluation (PRoBE) design. A total of 50 cholangiocarcinoma and...
| Autores principales: | , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
SAGE-Hindawi Access to Research
2011
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3170848/ https://www.ncbi.nlm.nih.gov/pubmed/21994874 http://dx.doi.org/10.4061/2011/873548 |